It has been elucidated that elevated glucose upregulates PIASy expression and that the SUMO E3 ligase PIASy mediates high-glucose-induced NF-κB inflammatory signalling, suggesting that PIASy is a potential therapeutic target for DN (Huang et al., 2017). Here, NFKB1 is linked to liver dysplastic nodule.